{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T11:02:25Z","timestamp":1787482945828,"version":"build-2736575974"},"reference-count":5,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"published-print":{"date-parts":[[2014,5,1]]},"DOI":"10.1136\/jnnp-2013-306541","type":"journal-article","created":{"date-parts":[[2013,11,30]],"date-time":"2013-11-30T02:35:16Z","timestamp":1385778916000},"page":"589-590","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials"],"prefix":"10.1136","volume":"85","author":[{"given":"J.","family":"Kitley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. I.","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Elsone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,11,29]]},"reference":[{"key":"key-10.1136\/jnnp-2013-306541-1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1177\/1352458510396923","article-title":"High-risk syndrome for neuromyelitis optica: a descriptive and comparative study","volume":"17","author":"Collongues","year":"2011","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2013-306541-2","first-page":"460825","article-title":"Neuromyelitis optica: an antibody-mediated disorder of the central nervous system","author":"Oh","year":"2012","journal-title":"Neurol Res Int"},{"key":"key-10.1136\/jnnp-2013-306541-3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/practneurol-2012-000237","article-title":"A practical guide to the treatment of neuromyelitis optica","volume":"12","author":"Palace","year":"2012","journal-title":"Pract Neurol"},{"key":"key-10.1136\/jnnp-2013-306541-4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2013-306541-5","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2013-306541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:53:43Z","timestamp":1601056423000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2013-306541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,29]]},"references-count":5,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,4,10]]},"published-print":{"date-parts":[[2014,5,1]]}},"URL":"https:\/\/doi.org\/10.1136\/jnnp-2013-306541","relation":{},"ISSN":["0022-3050"],"issn-type":[{"value":"0022-3050","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11,29]]}}}